Starling Oncology, Inc.
STLN· Nasdaq
STLNStarling Oncology, Inc.
Filed Mar 12, 2026 · 10-K · 71 days after period end · 0001799191-26-000007
derived · Computed from the longer spans the company filed.
| Metric | Q4 2025dderived from reported figures | Q4 2024 | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures |
|---|---|---|---|---|
| Revenue | $141.96M | $100.27M | $85.79M | $71.42M |
| Net Income | -$7.51M | -$13.18M | -$18.75M | -$11.01M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Starling Oncology, Inc. · CIK 1799191 · Engraved from SEC EDGAR
ended Dec 31, 2025 · filed Mar 12, 2026 · 71 d after period end
